Student or educator? Sign up with your school email and get 6 months of Pro free.
Cited by 365

The DOI matches its Crossref record; 20 of the 20 references it cites were found in a registry or an index.

Polyclonal Evolution of Multiple Secondary KIT Mutations in Gastrointestinal Stromal Tumors under Treatment with Imatinib Mesylate

Wardelmann, Eva, Merkelbach-Bruse, Sabine, Pauls, Katharina, Thomas, Nadja, Schildhaus, Hans-Ulrich, Heinicke, Thomas, Speidel, Nicola, Pietsch, Torsten, Buettner, Reinhard, Pink, Daniel, Reichardt, Peter, Hohenberger, Peter · 2006 · Clinical Cancer Research

Abstract

Gastrointestinal stromal tumors (GIST) are characterized by a strong KIT receptor activation most often resulting from KIT mutations. In a smaller subgroup of tumors without KIT mutations, analogous activating mutations are found in the platelet-derived growth factor receptor α (PDGFRα) gene. Both PDGFRα and KIT receptors are targets of the tyrosine kinase inhibitor imatinib (Glivec) which has improved the treatment of advanced GISTs significantly. However, a subgroup of tumors show a secondary progress under therapy with imatinib after initial response. One possible mechanism of secondary resistance is the development of newly acquired KIT mutations. In the present study, we evaluated the frequency of such secondary KIT mutations in a series of GIST patients in which tumor tissue was resected under treatment. We examined one to seven different tumor areas in 32 cases (total of 104 samples) and found up to four newly acquired KIT mutations in 14 patients (43.8%). These were always located in exons encoding the first or second tyrosine kinase domain (exon 13, 14, or 17). Mutations were found only in a subset of samples analyzed from each case whereas others retained the wild-type sequence in the same region. There was never more than one new mutation in the same sample. Consistent with a secondary clonal evolution, the primary mutation was always detectable in all samples from each tumor. According to our results, the identification of newly acquired KIT mutations in addition to the primary mutation is dependent on the number of tissue samples analyzed and has high implications for further therapeutic strategies.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1158/1078-0432.ccr-05-1211

Cites

20 of 20 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 20 references

Cited by

See all 365

Metadata

Authors
Wardelmann, E., Merkelbach-Bruse, S., Pauls, K., Thomas, N., Schildhaus, H.-U., Heinicke, T., Speidel, N., Pietsch, T., Buettner, R., Pink, D., Reichardt, P., & Hohenberger, P.
Venue
Clinical Cancer Research
Published
2006-03-15
Volume
12
Issue
6
Pages
1743-1749
ISSN
  • 1078-0432 (ISSN-L)
  • 1557-3265
OpenAlex
W2170257914
Cited by
365
References
20
FWCI
20.48
Type
journal article
Language
en
Open access
closed

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Polyclonal Evolution of Multiple Secondary KIT Mutations in Gastrointestinal Stromal Tumors under Treatment with Imatinib Mesylate. https://app.cochat.ai/papers/10.1158/1078-0432.ccr-05-1211
The paper
Wardelmann, E., Merkelbach-Bruse, S., Pauls, K., Thomas, N., Schildhaus, H.-U., Heinicke, T., Speidel, N., Pietsch, T., Buettner, R., Pink, D., Reichardt, P., & Hohenberger, P. (2006). Polyclonal Evolution of Multiple Secondary KIT Mutations in Gastrointestinal Stromal Tumors under Treatment with Imatinib Mesylate. Clinical Cancer Research. https://doi.org/10.1158/1078-0432.ccr-05-1211

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.